glp 1 patent GLP-1 Landscape: Shifting Dimensions Beyond Diabetes Competing in the Post-Patent GLP-1

Naltrexone has long been a cornerstone in addiction treatment , particularly for alcohol use disorder (AUD) and opioid use disorder (OUD)

By modulating dopamine levels, these medications could potentially impact the reinforcing effects of addictive behaviors

Its an individualized and unique experience for each person

Currently, there are other dual GIPR/GLP-1R agonists available, such as GLP-1R/GR (glucagon receptor), GLP-1R/AR (amylin receptor), and GLP-1R/NPYR (peptide YY binds to neuropeptide Y receptors) [36, 115] and even triple agonists that can activate GIPR to treat obesity and T2DM

But large clinical trials show these medications also reduce the risk of heart attack, stroke, and cardiovascular death benefits that weight loss alone cant fully explain

Digital coaching, behavioral support, weight maintenance programs, and payer/health system alignment will be increasingly core to outcomes and reimbursement